Analysts have been eager to weigh in on the Healthcare sector with new ratings on Annexon Biosciences (ANNX – Research Report), Medtronic (MDT – Research Report) and Progyny (PGNY – Research Report).
Annexon Biosciences (ANNX)
In a report released today, Joseph Stringer from Needham maintained a Buy rating on Annexon Biosciences, with a price target of $16.00. The company’s shares closed last Wednesday at $2.88.
According to TipRanks.com, Stringer is a 1-star analyst with an average return of
Annexon Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $15.75, representing a 460.5% upside. In a report issued on December 14, Wells Fargo also maintained a Buy rating on the stock with a $11.00 price target.
See today’s best-performing stocks on TipRanks >>
Medtronic (MDT)
In a report released today, Ryan Zimmerman from BTIG maintained a Hold rating on Medtronic. The company’s shares closed last Wednesday at $80.61.
According to TipRanks.com, Zimmerman is a 4-star analyst with an average return of
Medtronic has an analyst consensus of Moderate Buy, with a price target consensus of $88.20, a 7.8% upside from current levels. In a report issued on December 7, Piper Sandler also assigned a Hold rating to the stock with a $87.00 price target.
Progyny (PGNY)
BTIG analyst David Larsen reiterated a Buy rating on Progyny yesterday and set a price target of $45.00. The company’s shares closed last Wednesday at $36.37.
According to TipRanks.com, Larsen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Progyny has an analyst consensus of Strong Buy, with a price target consensus of $46.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ANNX:
- Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
- Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint
- Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway
- Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
- Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference
